ECSP20050785A - Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) - Google Patents
Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat)Info
- Publication number
- ECSP20050785A ECSP20050785A ECSENADI202050785A ECDI202050785A ECSP20050785A EC SP20050785 A ECSP20050785 A EC SP20050785A EC SENADI202050785 A ECSENADI202050785 A EC SENADI202050785A EC DI202050785 A ECDI202050785 A EC DI202050785A EC SP20050785 A ECSP20050785 A EC SP20050785A
- Authority
- EC
- Ecuador
- Prior art keywords
- pyridin
- methyl
- ghrelin
- acyltransferase
- goat
- Prior art date
Links
- 102100038752 Ghrelin O-acyltransferase Human genes 0.000 title abstract 4
- 101710205760 Ghrelin O-acyltransferase Proteins 0.000 title abstract 4
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical group [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- RWXCVESEMJNNMF-UHFFFAOYSA-N oxadiazolo[5,4-b]pyridine Chemical group C1=CN=C2ON=NC2=C1 RWXCVESEMJNNMF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a compuestos de la Fórmula general I, I en donde los grupos R1 y R2 se definen de acuerdo con la reivindicación 1, que tienen propiedades farmacológicas valiosas, en particular, se fijan a ghrelin O-aciltransferasa (GOAT) y modulan su actividad. Los compuestos son adecuados para el tratamiento y la prevención de enfermedades que se pueden ver influenciadas por este receptor, tales como enfermedades metabólicas, en particular, obesidad.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18154824 | 2018-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP20050785A true ECSP20050785A (es) | 2020-09-30 |
Family
ID=61157050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202050785A ECSP20050785A (es) | 2018-02-02 | 2020-08-24 | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11254688B2 (es) |
| EP (1) | EP3746451B1 (es) |
| JP (1) | JP7015396B2 (es) |
| KR (1) | KR20200116978A (es) |
| CN (1) | CN111655700B (es) |
| AU (1) | AU2019215707A1 (es) |
| BR (1) | BR112020013082A2 (es) |
| CA (1) | CA3087826A1 (es) |
| CL (1) | CL2020001907A1 (es) |
| CO (1) | CO2020009299A2 (es) |
| CR (1) | CR20200332A (es) |
| EA (1) | EA202091805A1 (es) |
| EC (1) | ECSP20050785A (es) |
| IL (1) | IL276136A (es) |
| JO (1) | JOP20200190A1 (es) |
| MA (1) | MA53075A (es) |
| MX (1) | MX2020008053A (es) |
| PE (1) | PE20210174A1 (es) |
| PH (1) | PH12020551168A1 (es) |
| SG (1) | SG11202006125VA (es) |
| WO (1) | WO2019149657A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6651054B2 (ja) * | 2016-08-05 | 2020-02-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グレリンｏ−アシルトランスフェラーゼ（ｇｏａｔ）阻害薬として使用するためのオキサジアゾロピリジン誘導体 |
| JP7083397B2 (ja) | 2018-02-02 | 2022-06-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのトリアゾロピリミジン誘導体 |
| WO2019149658A1 (en) * | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| CA3087826A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| PL4153600T3 (pl) | 2020-05-22 | 2024-12-16 | Boehringer Ingelheim International Gmbh | Sposób ciągły wytwarzania 7-amino-5-metylo-[1,2,5]oksadiazolo[3,4- b]pirydynokarboksylanu alkilu |
| WO2021233882A1 (en) | 2020-05-22 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
| CA3241217A1 (en) * | 2021-12-16 | 2023-06-22 | Jian Jin | Heterocyclic compounds as 5ht2a biased agonists |
| CN114426516B (zh) * | 2022-02-16 | 2022-11-04 | 安徽有吉医药科技有限公司 | 一种2-氨基-3-溴吡啶的制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004082383A1 (en) | 2003-03-17 | 2004-09-30 | Basf Aktiengesellschaft | Use of triazolopyrimidines for combating nematode diseases of plants |
| CA2657660A1 (en) * | 2006-07-12 | 2008-01-17 | Merck & Co., Inc. | Substituted pyrazoles as ghrelin receptor antagonists |
| JP6017754B2 (ja) | 2007-02-15 | 2016-11-02 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルカゴン／ｇｌｐ−１受容体コアゴニスト |
| US8084454B2 (en) | 2007-04-11 | 2011-12-27 | Canbas Co., Ltd. | Compounds with anti-cancer activity |
| CA2687611A1 (en) | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Novel sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors |
| DK2158214T3 (da) | 2007-06-15 | 2011-12-05 | Zealand Pharma As | Glukagonanaloger |
| FR2934058B1 (fr) | 2008-07-15 | 2010-09-24 | Centre Nat Rech Scient | Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines |
| FR2933989B1 (fr) | 2008-07-16 | 2013-03-08 | Commissariat Energie Atomique | Procede de purification de microorganismes presents dans des echantillons liquides |
| FR2933975B1 (fr) | 2008-07-17 | 2011-02-18 | Servier Lab | Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
| WO2010070252A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| NZ593813A (en) | 2008-12-15 | 2013-02-22 | Zealand Pharma As | Glucagon analogues |
| JP5635531B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| JP5635529B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| ME02220B (me) | 2009-07-13 | 2016-02-20 | Zealand Pharma As | Analozi acilovanog glukagona |
| US20110078154A1 (en) | 2009-09-28 | 2011-03-31 | Accenture Global Services Gmbh | Recruitment screening tool |
| AR081975A1 (es) | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| EP2585482B1 (en) | 2010-06-24 | 2019-03-27 | Zealand Pharma A/S | Glucagon analogues |
| SG11201403377QA (en) | 2011-12-23 | 2014-07-30 | Zealand Pharma As | Glucagon analogues |
| JP6106179B2 (ja) | 2012-02-24 | 2017-03-29 | 武田薬品工業株式会社 | 芳香環化合物 |
| WO2013192388A1 (en) | 2012-06-20 | 2013-12-27 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA118034C2 (uk) | 2013-11-14 | 2018-11-12 | Елі Ліллі Енд Компані | Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази |
| EP3193939A4 (en) * | 2014-09-17 | 2018-10-24 | The Regents of The University of California | Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase |
| WO2016123275A1 (en) | 2015-01-30 | 2016-08-04 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| AR104672A1 (es) * | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| AR104673A1 (es) * | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| WO2017070680A1 (en) | 2015-10-22 | 2017-04-27 | Cavion Llc | Methods for treating angelman syndrome and related disorders |
| JP6651054B2 (ja) * | 2016-08-05 | 2020-02-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グレリンｏ−アシルトランスフェラーゼ（ｇｏａｔ）阻害薬として使用するためのオキサジアゾロピリジン誘導体 |
| NZ750126A (en) * | 2016-08-11 | 2022-07-01 | Cellix Bio Private Ltd | Compositions and methods for the treatment of irritable bowel syndrome |
| US10988487B2 (en) | 2016-08-29 | 2021-04-27 | Merck Sharp & Dohme Corp. | Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
| JP7083397B2 (ja) | 2018-02-02 | 2022-06-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのトリアゾロピリミジン誘導体 |
| CR20200331A (es) | 2018-02-02 | 2020-09-03 | Boehringer Ingelheim Int | Derivados de oxadiazolopirisdina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltrasferasa (goat) |
| CA3087826A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors |
| WO2019149658A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
-
2019
- 2019-01-28 CA CA3087826A patent/CA3087826A1/en not_active Abandoned
- 2019-01-28 MA MA053075A patent/MA53075A/fr unknown
- 2019-01-28 JO JOP/2020/0190A patent/JOP20200190A1/ar unknown
- 2019-01-28 WO PCT/EP2019/051989 patent/WO2019149657A1/en not_active Ceased
- 2019-01-28 PE PE2020001161A patent/PE20210174A1/es unknown
- 2019-01-28 US US16/966,483 patent/US11254688B2/en active Active
- 2019-01-28 AU AU2019215707A patent/AU2019215707A1/en not_active Abandoned
- 2019-01-28 EP EP19702246.0A patent/EP3746451B1/en active Active
- 2019-01-28 CN CN201980010416.2A patent/CN111655700B/zh active Active
- 2019-01-28 SG SG11202006125VA patent/SG11202006125VA/en unknown
- 2019-01-28 JP JP2020541873A patent/JP7015396B2/ja active Active
- 2019-01-28 MX MX2020008053A patent/MX2020008053A/es unknown
- 2019-01-28 KR KR1020207025417A patent/KR20200116978A/ko not_active Withdrawn
- 2019-01-28 EA EA202091805A patent/EA202091805A1/ru unknown
- 2019-01-28 CR CR20200332A patent/CR20200332A/es unknown
- 2019-01-28 BR BR112020013082-6A patent/BR112020013082A2/pt not_active Application Discontinuation
-
2020
- 2020-07-19 IL IL276136A patent/IL276136A/en unknown
- 2020-07-21 CL CL2020001907A patent/CL2020001907A1/es unknown
- 2020-07-28 CO CONC2020/0009299A patent/CO2020009299A2/es unknown
- 2020-07-31 PH PH12020551168A patent/PH12020551168A1/en unknown
- 2020-08-24 EC ECSENADI202050785A patent/ECSP20050785A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3746451B1 (en) | 2023-07-12 |
| US20210053985A1 (en) | 2021-02-25 |
| JOP20200190A1 (ar) | 2020-07-29 |
| BR112020013082A2 (pt) | 2020-12-01 |
| US11254688B2 (en) | 2022-02-22 |
| CL2020001907A1 (es) | 2020-10-30 |
| PH12020551168A1 (en) | 2021-05-31 |
| CR20200332A (es) | 2020-09-03 |
| MX2020008053A (es) | 2020-09-07 |
| CN111655700B (zh) | 2023-07-18 |
| PE20210174A1 (es) | 2021-01-29 |
| WO2019149657A1 (en) | 2019-08-08 |
| SG11202006125VA (en) | 2020-07-29 |
| CO2020009299A2 (es) | 2020-08-21 |
| CA3087826A1 (en) | 2019-08-08 |
| AU2019215707A1 (en) | 2020-07-09 |
| KR20200116978A (ko) | 2020-10-13 |
| JP7015396B2 (ja) | 2022-02-15 |
| IL276136A (en) | 2020-09-30 |
| EA202091805A1 (ru) | 2020-12-16 |
| JP2021512113A (ja) | 2021-05-13 |
| MA53075A (fr) | 2021-05-12 |
| EP3746451A1 (en) | 2020-12-09 |
| CN111655700A (zh) | 2020-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20050785A (es) | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) | |
| ECSP20050797A (es) | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat) | |
| ECSP20050791A (es) | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat) | |
| CO2019000601A2 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
| ECSP24026455A (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
| CO2018008173A2 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
| MX2022014648A (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b. | |
| ECSP17073191A (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
| CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| SV2018005723A (es) | Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos | |
| MX2017000485A (es) | Espirocicloheptanos como inhibidores de la cinasa rho (rock). | |
| CR20160321A (es) | Modulares de tetrahidropiridopirazinas de gpr6 | |
| NI201400043A (es) | 4 - fenil - piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| UY35312A (es) | Ácidos indaniloxidihidrobenzofuranilacéticos como agonistas del receptor acoplado a la proteína g40 | |
| ECSP20061378A (es) | COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma | |
| BR112016024936A2 (pt) | moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes | |
| MX2019004030A (es) | Inhibidores del receptor de glucocorticoides. | |
| UY35668A (es) | Derivados de azabencimidazol como agonistas de ampk y composiciones farmacéuticas que los contienen | |
| CL2020001461A1 (es) | Inhibidores de dopamina–b–hidroxilasa. |